Biomarkers Consortium
The Biomarkers Consortium brings together various partners to identify, develop and qualify potential biomarkers to improve drug development and regulatory decision-making.
Spotlight
Skip This Section
ANNOUNCING
The FDA approves FNIH biomarker qualification plan for the first surrogate endpoint in osteoporosis clinical trials
Spotlight
The FNIH Biomarkers Consortium launches a project to detect the earliest changes in rare neurodegenerative diseases.
Announcing
The FNIH Biomarkers Consortium launches a project to investigate new methods of detecting measurable residual disease in patients with acute myeloid leukemia.
Spotlight
The FNIH announces promising new data for Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)
Spotlight
The FNIH highlights the success of the ABC-CT program in advancing neuropsychiatric biomarkers for autism.
Vision
Improving health through meaningful measurements.
Mission
To create and lead cross-sector efforts that validate and qualify biomarkers and other drug development tools to accelerate better decision making for the development of new therapeutics and health technologies.